Outgoing CEO Jeff Leiden takes victory lap as Vertex's Trikafta stuns Wall Street

Natalie Grover

Reporter

The first set of quarterly sales for Vertex’s recently approved cystic fibrosis triplet — Trikafta — astounded analysts on Thursday, as outgoing company chief Jeff …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Outgoing CEO Jeff Leiden takes victory lap as Vertex's Trikafta stuns Wall Street

Natalie Grover

Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

Scholar Rock names new CEO, adds biotech veterans in C-suite rebuild

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

Exclusive: Can AI replace animal testing? A new biotech launches to find out

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Out­go­ing CEO Jeff Lei­den takes vic­to­ry lap as Ver­tex's Trikaf­ta stuns Wall Street

Reporter

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Outgoing CEO Jeff Leiden takes victory lap as Vertex's Trikafta stuns Wall Street